Karin Dilger

Freiburg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Suicidal attempt with eliglustat overdose.

Suicidal attempt with eliglustat overdose.

Journal: JIMD reports

Published: July 26, 2022

Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.

Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.

Journal: Alimentary pharmacology & therapeutics

Published: February 20, 2017

Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.

Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial.

Journal: United European gastroenterology journal

Published: November 22, 2016

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.

A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease.

Journal: Journal of Crohn's & colitis

Published: August 20, 2016

A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.

A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.

Journal: Gut

Published: November 12, 2014

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.

Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.

Journal: Gut

Published: September 01, 2014

The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study.

The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: July 12, 2014

Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.

Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.

Journal: Journal of Crohn's & colitis

Published: September 02, 2013

Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.

Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.

Journal: Inflammatory bowel diseases

Published: February 08, 2013

Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.

Active eosinophilic esophagitis is associated with impaired elimination of budesonide by cytochrome P450 3A enzymes.

Journal: Digestion

Published: August 02, 2012

Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.

Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.

Journal: Basic & clinical pharmacology & toxicology

Published: November 28, 2011

Showing 1-11 of 11

Last Updated: 09/26/2026